SEC For		Α			TEC C	ECUDITI			יבי	ИСЦА				SCION					
	FORM	UNITED STATES SECURITIES AND EXCHANGE COM Washington, D.C. 20549											331011		OMB APPROVA				
Section 16. Form 4 or Form 5 obligations may continue. See					ENT OF CHANGES IN BENEFICIAL OWNE ed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940									SHIP	Estim	OMB Number: 323 Estimated average burden hours per response:			
1. Name and Address of Reporting Person <sup>*</sup> Martin Samuel Bates					2. Issuer Name <b>and</b> Ticker or Trading Symbol Celldex Therapeutics, Inc. [ CLDX ]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) C/O CEI	ast) (First) (Middle) O CELLDEX THERAPEUTICS, INC.				3. Date of Earliest Transaction (Month/Day/Year) 06/15/2023								2	X below) below) SVP AND CFO					
53 FRONTAGE ROAD, SUITE 220					4. If Amendment, Date of Original Filed (Month/Day/Year)								Line	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
(Street) HAMPTON NJ 08827														Form filed by More than One Reporting Person					
(City) (State) (Zip)					Rule 10b5-1(c) Transaction Indication   Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
		Tab	le I - Nor	n-Deriv	ative Se	ecurities A	cq	juired, l	Disp	osed o	of, o	r Bene	eficiall	y Owned	I				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					2A. Deemed Execution Date, if any (Month/Day/Year		Code (Instr.		4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)		(A) or 3, 4 and	A) or , 4 and Beneficially Owned Follo Reported		Form (D) o	: Direct	7. Nature of Indirect Beneficial Ownership			
						Code V		Amount	t (A) or (D)		Price	Transac (Instr. 3	tion(s)			(Instr. 4)			
		-				urities Acc ls, warrant								Owned					
1. Title of Derivative Security (Instr. 3)	2. 3. Transaction Or Exercise (Month/Day/Year) 34. Deemu Execution Derivative Security (Month/Day/Year) (Month/Da		Date, T	ransaction Code (Instr.		i. Date Exercisable and Expiration Date Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	Derivative Security Securities		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownershi (Instr. 4)			

Date Exercisable

06/15/2024<sup>(2)</sup>

(D)

Expiration Date

06/15/2033

Title

Common Stock

Explanation of Responses:

\$36.87

06/15/2023<sup>(1)</sup>

Incentive Stock Option (right to buy)<sup>(1)</sup>

1. Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

2. 25% vest on June 15, 2024 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

<u>/s/ Anthony S. Marucci,</u> <u>attorney-in-fact for Samuel</u> <u>Bates Martin</u>

Amount or Number of Shares

80,000

06/20/2023

80,000

D

\*\* Signature of Reporting Person Date

\$<mark>0</mark>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $\ast$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code V (A)

Α

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

and 5)

80,000